Join Growin Stock Community!

Bausch health companies inc.BHC.US Overview

US StockHealthcare
(No presentation for BHC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BHC AI Insights

BHC Overall Performance

BHC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BHC Recent Performance

-4.62%

Bausch health companies inc.

-3.61%

Avg of Sector

-2.16%

S&P500

BHC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BHC Key Information

BHC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BHC Profile

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Price of BHC

BHC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BHC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.42
PE Ratio (TTM)
14.12
Forward PE
1.41
PS Ratio (TTM)
0.21
PB Ratio
18.78
Price-to-FCF
2.14
METRIC
VALUE
vs. INDUSTRY
Gross Margin
70.65%
Net Margin
1.53%
Revenue Growth (YoY)
6.66%
Profit Growth (YoY)
5.99%
3-Year Revenue Growth
8.43%
3-Year Profit Growth
9.04%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.42
PE Ratio (TTM)
14.12
Forward PE
1.41
PS Ratio (TTM)
0.21
PB Ratio
18.78
Price-to-FCF
2.14
Gross Margin
70.65%
Net Margin
1.53%
Revenue Growth (YoY)
6.66%
Profit Growth (YoY)
5.99%
3-Year Revenue Growth
8.43%
3-Year Profit Growth
9.04%
  • When is BHC's latest earnings report released?

    The most recent financial report for Bausch health companies inc. (BHC) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BHC's short-term business performance and financial health. For the latest updates on BHC's earnings releases, visit this page regularly.

  • Where does BHC fall in the P/E River chart?

    According to historical valuation range analysis, Bausch health companies inc. (BHC)'s current price-to-earnings (P/E) ratio is 14, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of BHC?

    According to the latest financial report, Bausch health companies inc. (BHC) reported an Operating Profit of 474M with an Operating Margin of 16.95% this period, representing a decline of 15.05% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BHC's revenue growth?

    In the latest financial report, Bausch health companies inc. (BHC) announced revenue of 2.8B, with a Year-Over-Year growth rate of 9.26%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BHC have?

    As of the end of the reporting period, Bausch health companies inc. (BHC) had total debt of 20.85B, with a debt ratio of 0.79. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BHC have?

    At the end of the period, Bausch health companies inc. (BHC) held Total Cash and Cash Equivalents of 1.33B, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BHC go with three margins increasing?

    In the latest report, Bausch health companies inc. (BHC) did not achieve the “three margins increasing” benchmark, with a gross margin of 71.5%%, operating margin of 16.95%%, and net margin of -4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BHC's profit trajectory and future growth potential.

  • Is BHC's EPS continuing to grow?

    According to the past four quarterly reports, Bausch health companies inc. (BHC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BHC?

    Bausch health companies inc. (BHC)'s Free Cash Flow (FCF) for the period is 403M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BHC?

    The latest valuation data shows Bausch health companies inc. (BHC) has a Price-To-Earnings (PE) ratio of 14 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.